Olalla Figueroa-Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olalla Figueroa-Silva has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Maria Eugenia Gil-Pallares
Eidgenössische Technische Hochschule Zürich , Zürich
5 shared publications - Pedro Gil-Pallares
Department of Dermatology, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain
5 shared publications - Alba Navarro-Bielsa
Dermatology, Hospital Universitario Miguel Servet, Universidad de Zaragoza, IIS Aragón, Zaragoza, Spain
3 shared publications - José Manuel Suárez Peñaranda
Department of Pathology, Clinical University Hospital of Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Galician Healthcare Service (SERGAS), University of Santiago de Compostela, Santiago de Compostela, Spain
3 shared publications - Laura Taboada Paz
Department of Dermatology, Complejo Hospitalario Universitario de Ferrol, Spain
3 shared publications - Benigno Monteagudo
Dermatology Department Complejo Hospitalario Universitario de Ferrol Ferrol (A Coruña) Spain
2 shared publications
Latest Publications
- 6 February 2025
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 47 (5) , 373-378
Comparison of the IHC Expression of p16, p53, and MIB-1 in Extragenital Skin Bowenoid Lesions With High- and Low- Chronic Sun Damage
Background: Bowen disease and bowenoid actinic keratosis are difficult to distinguish due to overlapping histopathology. This study evaluates the role of p16, p53, and MIB-1 staining patterns in differentiating high-chronic sun damage (H-CSD) and low-chronic sun damage bowenoid lesions. Methods: Sixty extragenital in situ squamous cell carcinomas were included. Lesions with elastosis were considered H-CSD. P16, p53, and MIB-1 staining patterns were classified as block, gradient, or focal. Results: Seventy-two percent of lesions were H-CSD. Full-thickness dysplasia was observed in all lesions, and basal layer involvement in 97%. P16 staining was positive in 80%, matching areas of higher atypia, with block pattern more frequent in H-CSD (58% vs. 47%, P = 0.047). P53 was positive in 47%, with block pattern more common in H-CSD (40% vs. 18%, P = 0.02). MIB-1 was positive in all cases. P16 and MIB-1 patterns coincided in 75%, independently of sun exposure. Conclusions: P16 and p53 expression may be less frequent in bowenoid lesions than previously described. Histopathological features like basal layer and adnexal or follicular involvement may not differentiate H-CSD from low-chronic sun damage lesions or Bowen disease from bowenoid actinic keratosis. Variations in p16, p53, and MIB-1 staining could indicate different dysplasia pathways, although further studies are needed to clarify their prognostic significance.
- 6 February 2025
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 47 (5) , 373-378
Comparison of the IHC Expression of p16, p53, and MIB-1 in Extragenital Skin Bowenoid Lesions With High- and Low- Chronic Sun Damage
Background: Bowen disease and bowenoid actinic keratosis are difficult to distinguish due to overlapping histopathology. This study evaluates the role of p16, p53, and MIB-1 staining patterns in differentiating high-chronic sun damage (H-CSD) and low-chronic sun damage bowenoid lesions. Methods: Sixty extragenital in situ squamous cell carcinomas were included. Lesions with elastosis were considered H-CSD. P16, p53, and MIB-1 staining patterns were classified as block, gradient, or focal. Results: Seventy-two percent of lesions were H-CSD. Full-thickness dysplasia was observed in all lesions, and basal layer involvement in 97%. P16 staining was positive in 80%, matching areas of higher atypia, with block pattern more frequent in H-CSD (58% vs. 47%, P = 0.047). P53 was positive in 47%, with block pattern more common in H-CSD (40% vs. 18%, P = 0.02). MIB-1 was positive in all cases. P16 and MIB-1 patterns coincided in 75%, independently of sun exposure. Conclusions: P16 and p53 expression may be less frequent in bowenoid lesions than previously described. Histopathological features like basal layer and adnexal or follicular involvement may not differentiate H-CSD from low-chronic sun damage lesions or Bowen disease from bowenoid actinic keratosis. Variations in p16, p53, and MIB-1 staining could indicate different dysplasia pathways, although further studies are needed to clarify their prognostic significance.
- 27 July 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (1) , 56-61
Breslow density ability to predict melanoma survival: should it be used in clinical practice?
Background: Breslow density (BD) is an estimation of melanoma volume, which has emerged as a novel histopathological prognostic biomarker. Objectives: To evaluate the role of BD as a predictor of patients’ survival and assess its prognostic value in relation to overall survival (OS), disease-free survival (DFS), melanoma-specific survival (MSS) and metastasis-free survival (MFS). Methods: A retrospective observational study in a cohort of 107 patients with invasive melanoma was conducted. Kaplan–Meier and Log-rank tests were used for 10-year survival analysis. The ability of BD and Breslow thickness (BT) to predict survival was assessed using receiver operating characteristic curves. Results: The average follow-up was 115 months, excluding deaths. People with BD ≥ 65% showed lower survival rates compared with the BD < 65% group (log-rank test P < 0.001). Area under the curve (AUC) of BD ≥ 65% was higher than BTs for all studied survival rates except for MSS, in which absolute BD showed the highest value. Conclusions: BD is proposed as a simple, valuable and inexpensive histopathological feature that could provide additional valuable information to that available from melanoma staging, as it has proved to have a statistically significant prognostic value in relation to survival in patients with melanoma and comparable 10-year survival prediction ability with that of BT.
- 27 July 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (1) , 56-61
Breslow density ability to predict melanoma survival: should it be used in clinical practice?
Background: Breslow density (BD) is an estimation of melanoma volume, which has emerged as a novel histopathological prognostic biomarker. Objectives: To evaluate the role of BD as a predictor of patients’ survival and assess its prognostic value in relation to overall survival (OS), disease-free survival (DFS), melanoma-specific survival (MSS) and metastasis-free survival (MFS). Methods: A retrospective observational study in a cohort of 107 patients with invasive melanoma was conducted. Kaplan–Meier and Log-rank tests were used for 10-year survival analysis. The ability of BD and Breslow thickness (BT) to predict survival was assessed using receiver operating characteristic curves. Results: The average follow-up was 115 months, excluding deaths. People with BD ≥ 65% showed lower survival rates compared with the BD < 65% group (log-rank test P < 0.001). Area under the curve (AUC) of BD ≥ 65% was higher than BTs for all studied survival rates except for MSS, in which absolute BD showed the highest value. Conclusions: BD is proposed as a simple, valuable and inexpensive histopathological feature that could provide additional valuable information to that available from melanoma staging, as it has proved to have a statistically significant prognostic value in relation to survival in patients with melanoma and comparable 10-year survival prediction ability with that of BT.
- 30 April 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 49 (11) , 1301-1308
Tumour budding as a risk factor for lymph node metastases in cutaneous squamous cell carcinoma: a systematic review and meta-analysis
Background: Current staging systems have limitations in stratifying high-risk cutaneous squamous cell carcinoma (cSCC). Tumour budding (TB) has emerged as a potential prognostic factor in various cancers. Objectives: To evaluate the prognostic significance of TB in predicting lymph node metastases (NM) in cSCC. Methods: A comprehensive search of the PubMed, Web of Science, Embase and Cochrane databases was conducted. Studies investigating the association of TB using a 5-bud cutoff and NM in cSCC were included. A meta-analysis was performed using odds ratios (OR) to evaluate the association between TB and NM. Results: Six retrospective studies comprising 793 patients with cSCC were included. The random-effects analysis showed a significant association between high TB (≥ 5 buds) and NM (OR = 13.29, 95% confidence interval 5.55–31.86). Discussion: TB is a promising histopathological feature for predicting NM in cSCC. The results show a strong association between high TB and NM, supporting its utility as a risk factor for NM in cSCC. Its inclusion in clinical practice and cSCC staging might be helpful in the stratification of patients with high-risk cases and to guide optimal management strategies for each patient. However, further investigation is needed to determine standardized reporting guidelines for TB in cSCC.
- 30 April 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 49 (11) , 1301-1308
Tumour budding as a risk factor for lymph node metastases in cutaneous squamous cell carcinoma: a systematic review and meta-analysis
Background: Current staging systems have limitations in stratifying high-risk cutaneous squamous cell carcinoma (cSCC). Tumour budding (TB) has emerged as a potential prognostic factor in various cancers. Objectives: To evaluate the prognostic significance of TB in predicting lymph node metastases (NM) in cSCC. Methods: A comprehensive search of the PubMed, Web of Science, Embase and Cochrane databases was conducted. Studies investigating the association of TB using a 5-bud cutoff and NM in cSCC were included. A meta-analysis was performed using odds ratios (OR) to evaluate the association between TB and NM. Results: Six retrospective studies comprising 793 patients with cSCC were included. The random-effects analysis showed a significant association between high TB (≥ 5 buds) and NM (OR = 13.29, 95% confidence interval 5.55–31.86). Discussion: TB is a promising histopathological feature for predicting NM in cSCC. The results show a strong association between high TB and NM, supporting its utility as a risk factor for NM in cSCC. Its inclusion in clinical practice and cSCC staging might be helpful in the stratification of patients with high-risk cases and to guide optimal management strategies for each patient. However, further investigation is needed to determine standardized reporting guidelines for TB in cSCC.
- Open Access
- 1 March 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 98 (2) , 176-180
O atraso no diagnóstico causado pelo lockdown da COVID‐19 piorou o prognóstico do melanoma?
- 1 March 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 98 (2) , 176-180
Open AccessO atraso no diagnóstico causado pelo lockdown da COVID‐19 piorou o prognóstico do melanoma?
- Open Access
- 8 December 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 98 (2) , 176-180
Did COVID-19 lockdown delay actually worsen melanoma prognosis?
- 8 December 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 98 (2) , 176-180
Open AccessDid COVID-19 lockdown delay actually worsen melanoma prognosis?
- 4 November 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (5) , E628-E630
Unilateral facial actinic elastotic plaque: A distinct but underreported manifestation of solar elastosis
- 4 November 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (5) , E628-E630
Unilateral facial actinic elastotic plaque: A distinct but underreported manifestation of solar elastosis
- 14 October 2022
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 30 (10) , 674-680
Machine Learning Techniques in Predicting BRAF Mutation Status in Cutaneous Melanoma From Clinical and Histopathologic Features
Melanoma is the cutaneous neoplasm responsible for more patient deaths in all countries. BRAF mutations are the most common driver mutation and with the development of molecular targeted therapy, the precise knowledge of BRAF status has become increasingly important. Evaluation of BRAF mutation status has routinely been performed by polymerase chain reaction, a time consuming and expensive technique. Immunohistochemistry has been suggested as a cheaper alternative, but it has not gained general acceptance. A retrospective observational study in a cohort of 106 patients with invasive melanoma was conducted in order to develop and evaluate a machine learning approach to predict BRAF status using clinical and histologic variables. We compared the performance of different common machine learning algorithms and use SHapley Additive exPlanations (SHAP) to explain individual predictions and extract medical insights to define a heuristic model to estimate BRAF mutation probability. The Extreme Gradient Boosting algorithms obtained the best performance. Interpretability of models shows that the most important variables to estimate BRAF mutation probability are: age, Breslow thickness, and Breslow density. Based in this interpretation and medical knowledge, a simplify heuristic model is proposed to predict BRAF status using only 7 variables and obtain a performance of 0.878 of area under the curve. We propose a heuristic model that could be used by clinicians to obtain a good estimator of BRAF mutation probability.
- 14 October 2022
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 30 (10) , 674-680
Machine Learning Techniques in Predicting BRAF Mutation Status in Cutaneous Melanoma From Clinical and Histopathologic Features
Melanoma is the cutaneous neoplasm responsible for more patient deaths in all countries. BRAF mutations are the most common driver mutation and with the development of molecular targeted therapy, the precise knowledge of BRAF status has become increasingly important. Evaluation of BRAF mutation status has routinely been performed by polymerase chain reaction, a time consuming and expensive technique. Immunohistochemistry has been suggested as a cheaper alternative, but it has not gained general acceptance. A retrospective observational study in a cohort of 106 patients with invasive melanoma was conducted in order to develop and evaluate a machine learning approach to predict BRAF status using clinical and histologic variables. We compared the performance of different common machine learning algorithms and use SHapley Additive exPlanations (SHAP) to explain individual predictions and extract medical insights to define a heuristic model to estimate BRAF mutation probability. The Extreme Gradient Boosting algorithms obtained the best performance. Interpretability of models shows that the most important variables to estimate BRAF mutation probability are: age, Breslow thickness, and Breslow density. Based in this interpretation and medical knowledge, a simplify heuristic model is proposed to predict BRAF status using only 7 variables and obtain a performance of 0.878 of area under the curve. We propose a heuristic model that could be used by clinicians to obtain a good estimator of BRAF mutation probability.
- 1 June 2022
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 86 (6) , 1410-1412
Volume tumor impact on melanoma survival assessed using Breslow density
- 1 June 2022
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 86 (6) , 1410-1412
Volume tumor impact on melanoma survival assessed using Breslow density
- Open Access
- 1 January 2017
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 23 (11)
Is it just a psoriasiform dermatitis?
Bazex syndrome (BS) is a rare paraneoplastic syndrome most frequently associated with squamous cell carcinomas of the upper aerodigestive tractand other tumours. Characteristically, cutaneous lesions precede the diagnosis of malignancy. We report a 72-year-old patient with 1-year history of acral dermatitis. The diagnosis of BS was based on the presence of psoriasiform acral dermatitis and the evidence of two simultaneous tumors (prostate adenocarcinoma and undifferentiated carcinoma ofthe submandibular gland). It is important to have this syndrome in mind since cutaneous features usually precede an underlying neoplasm.
- 1 January 2017
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 23 (11)
Open AccessIs it just a psoriasiform dermatitis?
Bazex syndrome (BS) is a rare paraneoplastic syndrome most frequently associated with squamous cell carcinomas of the upper aerodigestive tractand other tumours. Characteristically, cutaneous lesions precede the diagnosis of malignancy. We report a 72-year-old patient with 1-year history of acral dermatitis. The diagnosis of BS was based on the presence of psoriasiform acral dermatitis and the evidence of two simultaneous tumors (prostate adenocarcinoma and undifferentiated carcinoma ofthe submandibular gland). It is important to have this syndrome in mind since cutaneous features usually precede an underlying neoplasm.